Dan Skovronsky (Eli Lilly via Facebook)

Eli Lil­ly spot­lights ear­ly on­col­o­gy in first pipeline re­view since R&D shift

Two weeks in­to the Josh Bilenker era at Eli Lil­ly, the lega­cy phar­ma was ex­cit­ed to spot­light three ear­ly-stage “pri­or­i­ty” on­col­o­gy pro­grams as they is­sued their 2020 guid­ance. They al­so re­it­er­at­ed their in­vest­ment in Alzheimer’s de­vel­op­ment, in­clud­ing their drug for the new­ly rein­vig­o­rat­ed amy­loid hy­poth­e­sis.

The new guid­ance of­fers a hint as to what the hun­dreds-strong on­col­o­gy group at Lil­ly will look like now that the Loxo C-suite has tak­en the reigns, and how the new ex­ec­u­tives will ap­proach R&D. It al­so points to the un­re­lent­ing grip Alzheimer’s, both its de­bil­i­tat­ing im­pact on mil­lions and its once-in-a-life­time mar­ket po­ten­tial, has had on the minds of Big Phar­ma de­spite years of tri­al fail­ure.

“We’ve gots some im­por­tant bets on A-be­ta that are go­ing to play out in the near-term,” CSO Dan Skovron­sky told in­vestors. “We think this is an im­por­tant test of the amy­loid hy­poth­e­sis.”

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.